Continuing Medical Education
- Claiming credit for the AACR Virtual Meeting: Precision Medicine Strategies to Improve Therapy of DLBCL
- Commercial Support
- Disclosure Index
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this internet live activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming CME Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by Friday, November 12, 2021. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Statement of Educational Need, Target Audience, and Learning Objectives
Diffuse large B-Cell lymphoma is the most common type of non-Hodgkin lymphoma, with an estimated 150,000 new cases annually worldwide.
Lymphomas represent a remarkably heterogeneous set of cancers that have traditionally been subdivided histologically. As a result, treatments have been developed for each histological category of lymphoma irrespective of molecular differences among the tumors in each category. The advent of high-throughput sequencing of tumor genomes, exomes, and transcriptomes has revealed remarkable genetic and phenotypic heterogeneity within each lymphoma histological category. Current therapies for lymphoma work well for some patients and fail others, which has been traced to differences in the molecular features of lymphomas. Clinical trials have largely not kept pace with the rapidly expanding knowledge of lymphoma genetic subtypes and of specific genetic aberrations that promote their malignant behavior.
This virtual meeting will convene experts in lymphoma genetics, drug development, and clinical trials who will explore the current landscape of treatment, the rational development of new therapeutic regimens, and the design of precision medicine trials in the future – all in an effort to improve patient outcomes.
After participating in this CME activity, physicians should be able to:
- Discuss the current landscape of DLBCL therapy.
- Demonstrate an understanding of the heterogeneity that exists in lymphomas and how this impacts research and treatment options.
- Discuss the rational development of new therapeutic regimens and the design of precision medicine trials in the future.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity.
Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants which will be disclosed at the meeting.
Questions about CME?
Please contact the Office of CME at (215) 440-9300 or [email protected].